AnalystsDouglas MiehmDouglas Miehm's Stock Forecasts
AnalystsDouglas Miehm
Analyst Ranking
Top 29%
#1473 out of 5024 analysts
Average Return
+2.4%
Win Rate
49%18 out of 37
Risk vs Reward
Poor
Good
Douglas Miehm's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Oncolytics Biotech IncONCY | +111.84% | $0.64 | $1.36 | 2025-03-09 - 2025-09-18 | Buy |
Mannkind CorpMNKD | +63.56% | $3.43 | $5.61 | 2025-08-06 - 2025-09-18 | Buy |
Aurinia Pharmaceuticals IncAUPH | +59.81% | $5.15 | $8.23 | 2022-11-03 - 2023-11-03 | Buy |
Ligand Pharmaceuticals IncLGND | +52.59% | $93.32 | $142.40 | 2024-08-06 - 2025-08-06 | Buy |
Ligand Pharmaceuticals IncLGND | +47.60% | $99.60 | $147.01 | 2024-08-11 - 2025-08-11 | Buy |
Douglas Miehm Analyst Color
Get additional color on Douglas Miehm's coverage of popular stocks
Douglas Miehm's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Mannkind CorpMNKD | 3 | Buy | $8.00 | +42.60% | Maintains | 24 days ago |
Ligand Pharmaceuticals IncLGND | 6 | Buy | $185.00 | +8.93% | Maintains | a month ago |
Aurinia Pharmaceuticals IncAUPH | 9 | Buy | $9.00 | -30.18% | Maintains | 2 months ago |
Bausch Health Companies IncBHC | 19 | Hold | $10.00 | +45.14% | Maintains | 5 months ago |
Bausch & Lomb CorpBLCO | 13 | Buy | $17.00 | +10.53% | Maintains | 5 months ago |
Oncolytics Biotech IncONCY | 1 | Buy | $5.00 | +267.65% | Maintains | 6 months ago |
Crh Medical CorpCRHM | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Novadaq Technologies IncNVDQ1 | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.